Cellectar Biosciences (NASDAQ:CLRB) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Cellectar Biosciences (NASDAQ:CLRB) in a report published on Tuesday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

A number of other analysts have also recently commented on CLRB. LADENBURG THALM/SH SH began coverage on shares of Cellectar Biosciences in a report on Thursday, December 5th. They set a “buy” rating and a $13.00 target price for the company. Oppenheimer reissued a “market perform” rating on shares of Cellectar Biosciences in a research report on Wednesday, December 11th.

Cellectar Biosciences Price Performance

Shares of CLRB opened at $0.24 on Tuesday. The firm has a market capitalization of $10.07 million, a P/E ratio of -0.14 and a beta of 1.04. Cellectar Biosciences has a one year low of $0.22 and a one year high of $4.45. The business has a fifty day moving average of $0.76 and a 200 day moving average of $1.66.

Cellectar Biosciences (NASDAQ:CLRB) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter. Analysts expect that Cellectar Biosciences will post -1.59 EPS for the current fiscal year.

Institutional Investors Weigh In On Cellectar Biosciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CLRB. XTX Topco Ltd lifted its holdings in Cellectar Biosciences by 432.4% during the second quarter. XTX Topco Ltd now owns 63,304 shares of the biopharmaceutical company’s stock valued at $158,000 after purchasing an additional 51,413 shares in the last quarter. Sequoia Financial Advisors LLC bought a new stake in shares of Cellectar Biosciences during the 3rd quarter valued at $51,000. Rosalind Advisors Inc. raised its position in shares of Cellectar Biosciences by 35.7% during the 3rd quarter. Rosalind Advisors Inc. now owns 3,671,550 shares of the biopharmaceutical company’s stock valued at $7,857,000 after purchasing an additional 965,934 shares during the period. Oppenheimer & Co. Inc. purchased a new position in shares of Cellectar Biosciences during the 3rd quarter valued at $27,000. Finally, Geode Capital Management LLC raised its holdings in Cellectar Biosciences by 3.3% during the third quarter. Geode Capital Management LLC now owns 352,452 shares of the biopharmaceutical company’s stock valued at $754,000 after acquiring an additional 11,266 shares during the period. 16.41% of the stock is owned by hedge funds and other institutional investors.

Cellectar Biosciences Company Profile

Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.